Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial
- PMID: 38215773
- DOI: 10.1016/S2468-1253(23)00407-7
Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial
Conflict of interest statement
HWMvL declares research funding (to his institution) and receipt of equipment, materials, drugs, etc from Bayer, BMS, Celgene, Janssen, Incyte, Lilly, Merck, Nordic Pharma, Nordic, Philips, Roche, and Servier; and consulting fees (both to institution and personal) from BMS, Dragonfly, Lilly, Merck, Nordic Pharma, and Servier. BPLW has reveived research grants from BMS and was an unpaid member of the data safety monitoring board of Neo-AEGIS. JPR has received consulting fees from Intuitive Surgical. RvH has received consulting fees from Intuitive Surgical and Medtronic. TJW declares no competing interests.
Comment in
-
Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial - Authors' reply.Lancet Gastroenterol Hepatol. 2024 Feb;9(2):104-105. doi: 10.1016/S2468-1253(23)00445-4. Lancet Gastroenterol Hepatol. 2024. PMID: 38215774 No abstract available.
Comment on
-
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. doi: 10.1016/S2468-1253(23)00243-1. Epub 2023 Sep 18. Lancet Gastroenterol Hepatol. 2023. PMID: 37734399 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
